
Federico La Manna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8926021/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lineageâ€specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. Molecular Oncology, 2022, 16, 921-939.	4.6	10
2	Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Letters, 2022, 530, 156-169.	7.2	49
3	Patient-derived xenografts and organoids model therapy response in prostate cancer. Nature Communications, 2021, 12, 1117.	12.8	76
4	A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles. Cancers, 2020, 12, 1480.	3.7	10
5	Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. Frontiers in Oncology, 2020, 10, 1012.	2.8	24
6	A biomimetic 3D model of hypoxia-driven cancer progression. Scientific Reports, 2019, 9, 12263.	3.3	56
7	Metastases in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a033688.	6.2	36
8	CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer. Oncogene, 2017, 36, 4739-4749.	5.9	33
9	Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. International Journal of Molecular Sciences, 2017, 18, 1655.	4.1	23
10	Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. International Journal of Molecular Sciences, 2016, 17, 1375.	4.1	78
11	Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biology Open, 2016, 6, 133-140.	1.2	11
12	RANKL: A promising circulating marker for bone metastasis response. Oncology Letters, 2016, 12, 2970-2975.	1.8	26
13	Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. BMC Cancer, 2015, 15, 998.	2.6	7
14	First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. OncoTargets and Therapy, 2015, 8, 3613.	2.0	30
15	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	6
16	Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. OncoTargets and Therapy, 2014, 7, 1919.	2.0	9
17	Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. Future Oncology, 2014, 10, 2423-2427.	2.4	9
18	CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. Bone, 2014, 66, 214-222.	2.9	28